Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria :~* Aged 9 to 16 years on the day of inclusion~* Subject in good health, based on medical history and physical examination~* Provision of assent form/informed consent form signed by the subject and by the parent(s) or another legally acceptable representative~* Subject and parent(s)/legally acceptable representative(s) able to attend all scheduled visits and to comply with all trial procedures~* For a female subject of child-bearing potential, avoid becoming pregnant (use of an effective method of contraception or abstinence) for at least 4 weeks prior to first vaccination until at least 4 weeks after the last vaccination.~Exclusion Criteria :~* Personal or family history of thymic pathology (thymoma), thymectomy, or myasthenia~* For a female subject of child-bearing potential, known pregnancy or positive urine pregnancy test at Visit 1~* Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the first trial vaccination~* Breast-feeding woman~* Planned participation in another clinical trial during the present trial period~* Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy~* Known systemic hypersensitivity to any of the components of any of the trial vaccines or history of a life-threatening reaction to any of the trial vaccines or to a vaccine containing any of the same substances~* Chronic illness at a stage that could interfere with trial conduct or completion, in the opinion of the Investigator~* Current alcohol abuse or drug addiction that may interfere with the subject's ability to comply with trial procedures~* Receipt of blood or blood-derived products in the preceding 3 months that might interfere with the assessment of immune response~* Receipt of any vaccine in the 4 weeks preceding the first trial vaccination~* Planned receipt of any vaccine in the 4 weeks following the first trial vaccination~* Subject deprived of freedom by administrative or court order, or in an emergency setting, or hospitalized without his/her consent~* Febrile illness (temperature ≥38.0°C) or moderate or severe acute illness/infection on the day of vaccination, according to investigator judgment~* Thrombocytopenia, bleeding disorder or anticoagulants in the 3 weeks preceding inclusion contraindicating intramuscular vaccination~* Severe diseases with or without fever, convulsions or neurological abnormalities without treatment or in progression.

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: 16 Years
- Healthy Volunteers: t

Study Arms:
- CYD Dengue Vaccine Group (Type: EXPERIMENTAL): Sanofi pasteur's CYD Dengue vaccine group (Dengvaxia®)
- Control Vaccine Group (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete